Investors bought shares of Valeant Pharmaceuticals International Inc. (NYSE:VRX) on weakness during trading hours on Thursday. $522.09 million flowed into the stock on the tick-up and $498.90 million flowed out of the stock on the tick-down, for a money net flow of $23.19 million into the stock. Of all stocks tracked, Valeant Pharmaceuticals International had the 16th highest net in-flow for the day. Valeant Pharmaceuticals International traded down ($0.81) for the day and closed at $29.19

VRX has been the topic of several analyst reports. Guggenheim reiterated a “buy” rating and set a $55.00 price target on shares of Valeant Pharmaceuticals International in a report on Monday, April 25th. BMO Capital Markets reiterated a “buy” rating and set a $66.00 price target on shares of Valeant Pharmaceuticals International in a report on Friday, April 22nd. Rodman & Renshaw reiterated a “buy” rating and set a $105.00 price target on shares of Valeant Pharmaceuticals International in a report on Tuesday, April 26th. S&P Equity Research reiterated a “buy” rating on shares of Valeant Pharmaceuticals International in a report on Sunday, May 29th. Finally, Stifel Nicolaus lowered their price objective on shares of Valeant Pharmaceuticals International from $65.00 to $55.00 and set a “buy” rating on the stock in a research note on Wednesday, June 8th. Six analysts have rated the stock with a sell rating, fifteen have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $60.32.

The firm’s market cap is $9.99 billion. The firm’s 50-day moving average is $23.85 and its 200-day moving average is $37.97.

Valeant Pharmaceuticals International (NYSE:VRX) last posted its earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.40 EPS for the quarter, missing the consensus estimate of $1.48 by $0.08. The business earned $2.42 billion during the quarter, compared to analysts’ expectations of $2.47 billion. The company’s revenue was down 11.4% on a year-over-year basis. During the same period in the previous year, the company earned $2.14 EPS. On average, equities analysts forecast that Valeant Pharmaceuticals International Inc. will post $6.54 earnings per share for the current fiscal year.

In other news, CEO Joseph C. Papa bought 202,000 shares of the company’s stock in a transaction on Friday, June 10th. The stock was purchased at an average cost of $24.48 per share, for a total transaction of $4,944,960.00. Following the completion of the transaction, the chief executive officer now owns 2,442,199 shares of the company’s stock, valued at $59,785,031.52. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Argeris N. Karabelas bought 4,000 shares of the company’s stock in a transaction on Thursday, August 11th. The stock was purchased at an average price of $24.65 per share, with a total value of $98,600.00. Following the completion of the transaction, the director now directly owns 20,726 shares of the company’s stock, valued at approximately $510,895.90. The disclosure for this purchase can be found here.

Other institutional investors have recently bought and sold shares of the company. State of New Jersey Common Pension Fund D purchased a new position in Valeant Pharmaceuticals International during the fourth quarter valued at approximately $2,033,000. BNP Paribas Arbitrage SA boosted its stake in shares of Valeant Pharmaceuticals International by 253.0% in the fourth quarter. BNP Paribas Arbitrage SA now owns 284,308 shares of the specialty pharmaceutical company’s stock valued at $28,900,000 after buying an additional 203,760 shares during the last quarter. I.G. Investment Management LTD. boosted its stake in shares of Valeant Pharmaceuticals International by 31.0% in the fourth quarter. I.G. Investment Management LTD. now owns 1,328,610 shares of the specialty pharmaceutical company’s stock valued at $135,033,000 after buying an additional 314,616 shares during the last quarter. Finally, Nicholas Co. Inc. WI boosted its stake in shares of Valeant Pharmaceuticals International by 15.6% in the fourth quarter. Nicholas Co. Inc. WI now owns 1,586,925 shares of the specialty pharmaceutical company’s stock valued at $161,310,000 after buying an additional 214,435 shares during the last quarter.

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.